Skip to main content
Log in

Bevacizumab/icotinib/osimertinib

Various toxicities: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Zhang L, et al. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer. Chinese Medical Sciences Journal 34: 292-296, No. 4, Dec 2019. Available from: URL: http://doi.org/10.24920/003487

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab/icotinib/osimertinib. Reactions Weekly 1791, 49 (2020). https://doi.org/10.1007/s40278-020-74894-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-74894-1

Navigation